<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05482828</url>
  </required_header>
  <id_info>
    <org_study_id>B100013</org_study_id>
    <nct_id>NCT05482828</nct_id>
  </id_info>
  <brief_title>Effect of Jaeumgeonbi-Tang on Chronic Subjective Dizziness</brief_title>
  <official_title>Effect of Jaeumgeonbi-Tang on Chronic Subjective Dizziness: A Randomized, Double-Blind, Parallel-group, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Health Industry Development Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Health Industry Development Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to assess the safety and efficacy of JGT (Jaeumgeonbi-Tang). A&#xD;
      randomized, double-blind, parallel-group, placebo-controlled clinical trial was conducted and&#xD;
      changes in symptoms and quality of life of the patients were evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study's protocol was designed to assess the efficacy of JGT (Jaeumgeonbi-Tang) for&#xD;
      chronic subjective dizziness.&#xD;
&#xD;
        -  This design of the study is a randomized, double-blind, parallel-group,&#xD;
           placebo-controlled design.&#xD;
&#xD;
        -  Symptoms and quality of life of chronic subjective dizziness patients will be evaluated.&#xD;
&#xD;
        -  Dizziness severity and quality of life of the patients will be evaluated using DHI&#xD;
           (Dizziness Handicap Inventory) (1) before treatment (baseline), (2) after 2 weeks, and&#xD;
           (3) after 4 weeks of JGT treatment.&#xD;
&#xD;
        -  Blood samples of the patients will be gathered before and after JGT treatment for&#xD;
           pathophysiological analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    The Sponser doesn't fund any more&#xD;
  </why_stopped>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dizziness handicap Inventory</measure>
    <time_frame>Change from Baseline DHI score at 4 weeks</time_frame>
    <description>The DHI (Dizziness Handicap Inventory) is a 25-item self-report questionnaire that quantifies the effect of dizziness on daily life by measuring the self-perceived handicap of the patients.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Subjective Dizziness</condition>
  <arm_group>
    <arm_group_label>JGT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group: JGT (Jaeumgeonbi-Tang) tablet. 8 g t.i.d. for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group: Corn starch tablet, 8 g t.i.d. for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JGT (Jaeumgeonbi-Tang) tablet</intervention_name>
    <description>JGT tablet (composed of 19 herbs), 24 g daily (single dose=8 g), t.i.d. for 28 days</description>
    <arm_group_label>JGT group</arm_group_label>
    <other_name>JGT (Jaeumgeonbi-Tang) tablet, Hanpoong Co. Ltd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Corn starch tablet, 24 g daily (single dose=8 g), t.i.d. for 28 days</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Corn starch tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        [Inclusion Criteria]&#xD;
&#xD;
          -  Chronic subjective dizziness patients, aged from 20 to 65&#xD;
&#xD;
          -  DHI (Dizziness Handicap Inventory) score â‰¥ 24&#xD;
&#xD;
          -  Those who can fully comprehend the general protocol of this study and voluntarily&#xD;
             agree to participate&#xD;
&#xD;
        [Exclusion Criteria]&#xD;
&#xD;
          -  Inner ear disease (benign paroxysmal positional vertigo, vestibular neuritis,&#xD;
             Meniere's disease, etc.)&#xD;
&#xD;
          -  Dizziness secondary to specific diseases such as hypoglycemia, recent stroke (within&#xD;
             the last 6 months), or heart disease.&#xD;
&#xD;
          -  Use of medications that could influence the result of the study (anticonvulsants,&#xD;
             sedatives, antidepressants, sleeping pills, prostate medicine, Parkinson's drug,&#xD;
             dementia drug, etc.)&#xD;
&#xD;
          -  Pregnancy, breastfeeding, or plans of becoming pregnant&#xD;
&#xD;
          -  Functional dyspepsia (persistent, recurring abdominal pain, or discomfort)&#xD;
&#xD;
          -  Other allergic diseases&#xD;
&#xD;
          -  Ineligibility for other reasons in the opinion of the research clinician (when the&#xD;
             physician determines that there are significant physical or mental defects that the&#xD;
             patient cannot understand and follow the protocol)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoo HoRyong, KMD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Daejeon University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Daejeon Korean Medicine Hospital of Daejeon Unversity</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>July 28, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2022</study_first_posted>
  <last_update_submitted>July 28, 2022</last_update_submitted>
  <last_update_submitted_qc>July 28, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea Health Industry Development Institute</investigator_affiliation>
    <investigator_full_name>Ho Ryong Yoo</investigator_full_name>
    <investigator_title>Associate Professor, Daejeon University</investigator_title>
  </responsible_party>
  <keyword>Chronic subjective dizziness</keyword>
  <keyword>Oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vertigo</mesh_term>
    <mesh_term>Dizziness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

